A new generation of infectious
disease vaccines

Using its novel synthetic DNA vaccine technology, Inovio has created the potential for a new generation of infectious disease vaccines. This technology enables the design of synthetic vaccines targeting multiple antigens of a disease, with the genetic makeup of the antigen based on different strains of the pathogen to help provide broader preemptive protection against the inevitable mutations that occur.

We have developed SynCon® vaccines to not only prevent but treat a variety of infectious diseases. Our most advanced programs are in HIV and influenza, which are in clinical studies. We also have research and preclinical studies focused on hepatitis as well as malaria and other diseases, all areas of large unmet medical need. Many of these programs are being conducted and/or funded in collaboration with respected research organizations.